Beijing News (reporter Zhaohui Zhang) — On May 29, Chineo's broad-spectrum anti-cancer cell drug ScTIL — a supercharged TIL-like cell technology derived from peripheral blood — was unveiled at the 2023 Zhongguancun Forum.
ScTIL technology is an immunocyte therapy for solid tumors, which enhances peripheral blood circulating TIL (cTIL) cells by loading them with a receptor targeting PD-L1 and a CD19 CAR amplification factor. It has the potential to be effective regardless of cancer type, stage, or tumor mutation burden, and is suitable for the majority of cancer patients, with favorable safety and efficacy.
In recent years, tumor immunotherapy represented by PD-1 and CAR-T has achieved certain successes, but various therapies have their own limitations and insurmountable bottlenecks. The novel super-circulating TIL cell therapy (ScTIL), developed by Chineo, is constructed from peripheral blood circulating TIL-like cells expressing enhanced receptors and expansion factors. Peripheral blood circulating TIL-like cells overcome the heterogeneity of solid tumors and the surgical dependency for obtaining TIL cells. Enhanced receptor technology overcomes the tumor microenvironment, while expansion factor technology breaks through the bottleneck of T cell quantity, significantly shortening the in vitro preparation cycle and reducing in vitro preparation costs.
In addition, ScTIL cell therapy can not only control the progression of malignant solid tumors but also effectively eliminate circulating tumor cells in peripheral blood—a major source of tumor metastasis and recurrence. For early-stage cancer patients, combining surgery with ScTIL treatment can eradicate both the solid tumor and circulating tumor cells, reduce side effects and patient suffering, and eliminate the risks of recurrence and metastasis, transforming cancer from an incurable disease into a manageable, and potentially curable, chronic condition. The advent of ScTIL cell therapy will bring a revolutionary change to the treatment of solid tumors.
As of now, ScTIL cell therapy has initiated multiple clinical studies led by investigators targeting various types of cancer (ⅡT research), including collaborations with Peking Union Medical College Hospital on biliary tract tumors, gynecological tumors, and respiratory tract tumors.ⅡT Research, conducted by the First Affiliated Hospital of Zhengzhou University across all cancer typesⅡT Research, conducted by Shanghai East Hospital and Zhongshan Hospital Affiliated to Fudan University, focuses on pan-cancer studies.ⅡT research, etc.
Proofread by Baoqing Liu